An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion
South Korea Extends Bond Market Stabilization Measures Amid Rising Financial Risks
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
ASX Shares Slide After ASIC Imposes A$150 Million Capital Requirement
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks
Russia Stocks End Flat as Energy and Retail Shares Show Mixed Performance
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 



